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Summary Topoisomerase I inhibitors are new compounds of interest for cancer chemotherapy. We performed a study with Gl147211, a new
semisynthetic camptothecin analogue, to determine the absolute bioavailability of the drug given orally. Patients with a histologically
confirmed diagnosis of a solid tumour refractory to standard forms of therapy were eligible for the study. Gi147211 was given orally on day 1
and as a 30-min infusion daily on days 2-5. The treatment course was repeated every 3 weeks. In subsequent patient cohorts, the dose of
the oral formulation was escalated from 1.5 mg m-2 to 6.0 mg m-2; the dose for i.v. administration was fixed at 1.2 mg m-2. Plasma
pharmacokinetics was performed on day 1 and 2 of the first course and on day 1 of the second course using a validated high-performance
liquid chromatographic assay. Nineteen patients were entered into the study; one patient was not evaluable because the treatment course
was stopped prematurely. Eighteen patients received a total of 47 treatment courses. The absolute bioavailability of G1147211 averaged
1.3 ± 5.2%. Drug appeared quickly in plasma with a median Tma, at 0.5 h. Fasting orfed state had no significant influence on the bioavailability
of G1147211. The terminal half-life after administration of oral G1147211 was 6.85 ± 3.13h, similar to the half-life after intravenous
administration. The major toxicities were neutropenia and thrombocytopenia. Nadirs for neutropenia and thrombocytopenia occurred on day
8 and day 15 respectively. Other toxicities predominantly consisted of mild and infrequent nausea and vomiting, and fatigue. The oral
administration of the drug is well tolerated. Oral administration of topoisomerase I inhibitor G1147211 results in a low bioavailability with
relatively wide interpatient variation. The intravenous route of administration is advised for further development of this promising
topoisomerase I inhibitor.
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G1147211 [7-(methylpiperazinomethylene)-10,11-ethylenedioxy-
20(S)-camptothecin dihydrochloride] is a water-soluble semisyn-
thetic analogue of camptothecin (CPT). Early clinical trials with
CPT in the late 1960s showed activity of this plant alkaloid in a
variety of solid tumours. Its further development was stopped
because of unpredictable and severe myelosuppression, gastro-
intestinal toxicity and haemorrhagic cystitis (Gottlieb et al, 1970;
Creaven et al, 1972; Muggia et al, 1972).
Interest in CPT was renewed in the 1980s, because topoiso-
merase I was identified as the single cellulartarget ofCPT (Hsiang
et al, 1988 1989), and an overexpression of topoisomerase I was
found in various tumour cell lines but not in normal tissues
(Giovanella et al, 1989; Hirabayashi et al, 1992). Topoisomerase I
is a nuclear enzyme that resolves topological problems of the
torsionally strained (supercoiled) DNA by forming a covalent
adduct between topoisomerase I and the DNA, termed the cleav-
able complex. This catalytic intermediate creates single-strand
DNA breaks, allowing the DNA molecule to rotate around the
intact DNA strand at the cleavage site, leading to a relaxation of
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the DNA molecule, and in this way replication, transcription and
other DNA functions can proceed. These enzyme-bridged breaks
are then resealed by topoisomerase I (Champoux, 1976; Muller,
1985; Muller et al, 1985; Camilloni et al, 1989).
The sensitivity of malignant cells to topoisomerase I inhibitors
has been correlated positively with topoisomerase I activity
(Andoh et al, 1987; Gupta et al, 1988; Potmesil et al, 1988;
Giovanella et al, 1989; Eng et al, 1990; Sugimoto et al, 1990;
Tanizawa et al,'1992). It has been documented that camptothecin
(CPT) interferes with the breakage-reunion process of topoiso-
merase I by stabilizing the enzyme-DNA cleavable complexes
(Liu et al, 1989). Formation of these complexes results in various
effects, including inhibition of DNA replication, termination of
RNA transcription at sites of complex formation, induction of
expression of early-response genes, induction of differentiation
and ultimately internucleosomal DNA fragmentation - a charac-
teristic of programmed cell death or apoptosis (Bendixen et al,
1990; Kaufmann et al, 1991; Kharbanda et al, 1991; Nakaya et al,
1991; Aller et al, 1992; Wyllie et al, 1992).
Recently several semisynthetic CPT analogues (Slichenmyer et
al, 1993; Creemers et al, 1994; Potmesil, 1994) have been devel-
oped, aiming at reduced toxicity and sustained or improved activity.
One of these analogues, GI147211, demonstrated significant
cytotoxicity against several xenografts of human cancers,
including HT-29 and SW-48 colon, PC-3 prostate, MX-1 breast,
H460 lung, SKOV3 ovarian and KB epidermoid carcinomas
(Emerson et al, 1993, 1995).
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The relative effect on tumour growth was dose schedule depen-
dent, with a greater reduction in tumour volume achieved by
prolonged dosing. Animal toxicology studies by intravenous route
showed that myelosuppression was the main toxicity and was dose
limiting.
Previously we reported myelosuppression as being the main
toxicity of G1147211 administered intravenously to adult patients
with solid tumours on a daily xS schedule every 3 weeks (Gerrits
et al, 1996). Here, we present a bioavailability study in patients
with solid tumours using oral administration ofGI147211 on day 1




Patients with a histologically confirmed diagnosis of a solid
tumour refractory to standard forms of therapy were eligible for
the study. Other eligibility criteria included: (1) age 2 18 years; (2)
an Eastern Cooperative Oncology Group (ECOG) performance
status < 2; (3) an estimated life expectancy ofat least 3 months; (4)
no previous anti-cancer therapy for at least 4 weeks (3 months
for previous nitrosoureas or mitomycin C); (5) adequate
haematopoietic (WBC .4 x 109 1,-1, ANC 2 1.5 x 109 1-1, platelets
120 x 109 1-1 and Hgb > 6.0 mm 1-'), hepatic (bilirubin within
normal limits; AST, ALT < 2.0 x normal) and renal (serum creati-
nine < 140gmol 1-1) functions; and (6) no known brain and/
or leptomeningeal disease and no symptomatic peripheral
neuropathy. All patients gave written informed consent. Patients
with prior gastric ofupper gastrointestinal surgery were excluded.
Treatment and dose escalation
Patients were to be treated with G1147211 on a daily x 5 schedule
every 3 weeks. For the first two courses, patients received
G1147211 orally on day 1. G1147211 was given by infusion on
days 2-5 of the first two courses and for 5 days in subsequent
courses.
The anticipated oral bioavailability of G1147211 was around
15%. Thus, compared with an intravenous bioavailability of
100%, a higher oral dose would produce much less systemic expo-
sure. To provide a safe administration ofthe drug, the starting dose
was set at 1.5 mg m-2. Dose escalations ofthe oral administration
were based on the prior dose level toxicity and pharmacokinetic
profile. Ifnotoxicity was seen atthepriordose, < 100% dose esca-
lation ofthe oral dose was allowed. However, iftoxicity was seen,
a maximum dose escalation of 33-66% was allowed, determined
by the worst significant toxicity.
At least three patients were entered at each dose level. At the
highest oral dose, bioavailability of oral GI147211 was studied in
half of the patients after an overnight fast during the first course
and in a fed state during the second course.
The i.v. dose of G1147211 was fixed at 1.2 mg m-2 day-1,
according to the recommended dose forphase II studies (Gerrits et
al, 1996). Intrapatient dose escalation was not performed.
The maximum-tolerated dose (MTD) was defined as one dose
level below the dose that induced dose-limiting toxicities (DLT),
which were defined as at least one of the following: (1) ANC
< 0.5 x 109 1-1 or platelets < 50 x 109 1-1 for more than 5 days; (2)
ANC < 0.5 x 109 1-1 with fever requiring parenteral antibiotics,
and/or non-haematological toxicity 2 CTC grade 3 in more than
one-third of GI147211-naive patients (at least two of a maximum
of six patients).
G1147211 was supplied by Glaxo as a clear solution in vials of
2.0 ml. The vials contained a mixture of 0.5 mg of G1147211 and
100 mg of dextrose. The pH was adjusted to 3.5. GI147211 was
diluted in 5% dextrose. GI147211 for oral intake was mixed with
50 ml of 5% dextrose in a plastic dosing container and was
consumed within 1 min, after which an additional 50 ml of 5%
dextrose was used. The infusion bag (GI147211 + 5% dextrose)
contained exactly 100 ml and was administred as a 30-min infu-
sion on days 2 to 5.
Treatment assessment
Before therapy, medical history was taken and complete physical
examination, complete blood cell (CBC) count, serum chemistries,
including sodium, potassium, chloride, bicarbonate, calcium, phos-
phorus, creatinine, urea, uric acid, glucose, total protein, albumin,
bilirubin, alkaline phosphatase, AST and ALT, were performed, as
were urinalysis, coagulation parameters (APTT, PT), ECG and
chest radiography. Weekly evaluations between the courses
included history, physical examination, haematology and serum
chemistries and toxicity assessment according to the CTC criteria
(National Cancer Institute, 1988). Tumour measurements were
performed after every two courses and evaluated according to the
WHO criteria for response (World Health Organization, 1979);
patients were taken offprotocol in case ofdisease progression.
Pharmacokinetics
For pharmacokinetic analysis, whole blood samples (7 ml) were
collected in heparinized tubes from an indwelling i.v. cannula,
placed in the arm contralateral to that receiving the drug, before
dosing and at 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24
h after dosing on day 1 and 2 ofthe first course. Blood samples for
the second course were only obtained during day 1. Plasma was
harvested from blood. Blood samples were analysed for the
lactone and total G1147211 using a validated chromatographic
assay, according to the method published by Stafford et al (1995).
The area under the plasma concentration-time curve (AUC) was
calculated by non-compartmental analysis using the trapezoidal
method with extrapolation of the curve to infinity on day 1. The
absolute bioavailability was calculated as the ratio of the AUC
after oral and intravenous dosing.
F= AUC oral Dose i.v. x 100% AUC i.v. Dose oral
The intrapatient variability ofthe absolute oral bioavailability was
calculated according to:
F, F2 x 100%
Fl is absolute bioavailability during the first course and F2 is
bioavailability during the second course.
The terminal half-life was calculated as In2/X, where X is the
elimination rate constant.
The effect of feeding on oral bioavailability was tested with a
standard meal (breakfast) in eight patients at the highest oral dose
level.
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Table 2 Drug-related non-haematological toxicity per course (n = 47) (all
toxicities CTC grade 1)
Dose level
1.5mg m-2 3.0mg m-2 6.0mg m-2 Total
Nauseaa 4 4 16 24
Vomitingb 2 2 7 11
Fatiguec 4 2 10 16
Diarrhoea 0 0 1 1
Stomatitis 0 1 1 2
Abdominal discomfort 0 3 3 6
aNo difference between oral and intravenous administration. bTwo courses




1 delay of 2 weeks. Treatment delay occurred in five patients on
dose level 6.0 mg m-2 and in one patient at dose level 3.0 mg m-2.
Statistical methods
The paired t-test and Wilcoxon signed-rank test were used for
statistical analysis on T tl,2 and AUC.
RESULTS
A total of 19 patients entered the study. Patient characteristics are
given in Table 1. One patient requested to be taken off study after
3 days ofdrug administration. In another patient, tumour response
could not be evaluated as only one course was given because of
toxicity. The total number ofevaluable courses was 47.
In total, 17 patients were evaluable for response. The median
number of courses per patient was two (range 1-6). Seven patients
received three or more treatment courses.
Dose levels studied for the oral dosing of G1147211 were
1.5 mg m-2, 3.0 mg m-2and 6.0 mg m-2. In order to study the influ-
ence of a fed vs fasting state on pharmacokinetics oforally admin-
istered GI147211, eight additional patients were recruited at the
highest dose level.
Haematological toxicity
Neutropenia and thrombocytopenia were the major side-effects
observed. Myelotoxicity was notobserved atthefirst two dose levels.
At the third oral dose level (6.0 mg m-2), CTC grade III-IV granulo-
cytopenia and thrombocytopenia were seen in respectively, 5 out of
30 and 4 out of 30 courses. The ANC nadir at this dose level was
0.09 x 109 1-' in the one case with CTC grade IV and 0.73-
0.98 x 109 1-1 in the two cases with CTC grade III granulocytopenia.
Threepatients developed CTC grade Ill-IV thrombocytopenia with a
median platelet count of 25 x 109 1-1 (range 4-40 x 109 1-1). The
median duration of severe myelosupression, expressed as the number
of days between the first occurrence and recovery to CTC grade II
toxicity was 7 days (range 7-19 days) for granulocytopenia and 8
days forthrombocytopenia (range 3-16 days).
CTC grade I-II anaemia occurred regularly; erythrocyte transfu-
sions were given in 24 out of 47 courses. Mild leucopenia CTC
grade I-IH occurred in 17 (36.2%) of 47 courses. Treatment delay
because of slow recovery of mild leucopenia occurred in six
patients: five patients had a delay of 1 week, one patient had a
Non-haematological toxicity
Overall, non-haematological toxicities wererelatively mild(Table2).
Nausea and vomiting occurred in 24 (51.6%) and 9 (19.1%) of
47 courses, respectively, and were CTC grade I. Vomiting CTC
grade II was present in two (4.2%) cycles. Nausea and vomiting
after oral administration was not different when compared with
intravenous dosing of the drug. Nausea and vomiting were only
present during the period of drug administration and could easily
be circumvented by the prophylactic use of standard antiemetics.
Patients (34%) frequently complained of mild fatigue. Abdominal
discomfort, mostly cramping, occurred in six (13%) courses.
Alopecia grade I was observed in three patients (17%). Mild
headache was not dose dependent and occurred in two courses
(4.2%); reversible CTC grade I peripheral neuropathy was
reported in one patient (2.1%). Mild stomatitis occurred in two
patients, and one patient developed mild diarrhoea grade I. Renal
and liver toxicity were not reported. Neutropenic sepsis in one
patient was the main serious adverse event during administration
ofGI147211.
Pharmacokinetics
At the dose level of6.0 mg m-2, plasma concentration-time curves
of oral lactone and total GI147211 could be measured up to 12 h
after administration in 68% of courses. Plasma concentrations
could be measured at 24 h in 21% of courses of oral GI147211
administration.
T was < 0.5 h in 13 of 19 cases. Mean Tmax after oral dosing
was 0.63 ± 0.40 h (Table 3). At the dose level of 6.0 mg m-2, T
after oral administration was not significantly influenced by a fed
or fasted state (P = 0.17) (Table 4).
The mean maximal plasma concentration (Cmax) at the
6.0 mg m-2 dose level was 4.02 ± 3.57 ng ml-' after oral and
21.76 mg ml ± 6.37 ng ml' after intravenous dosing. The mean
AUC oflactone GI147211 after oral dosing at the 6.0 mg m-2 dose
level was 20.3 ± 20.2 ng h ml-' and 32.1 ± 13.5 ng h ml-' after
intravenous administration of 1.2 mg m-2.
The absolute bioavailability of G1147211 lactone was
11.3 ± 5.2%. Absolute bioavailability ranged from 4.8% to 24.3%.
Absolute bioavailability based on total G1147211 (lactone plus
acid) was similar to the one observed with lactone alone. Absolute
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Table 3 Pharmacokinetic data of 19 patients after oral dosing (day 1) and after intravenous administration (days 2-5) of Gl147211. Bioavailability of lactone
and total G1147211
Patient i.v. Dose i.v. AUC i.v. t1,2 Oral dose OralCm,X Oral Tmax Oral AUC lactone Oral AUC total Oralt,12 Absolute
(mg m-3) (ng h ml-') (h) (mg m-2) (ng ml-') (h) (ng h ml-') (ng h ml-') (h) bioavailability
Lactone (%) Total (%)
1 1.2 22.29 6.2 1.5 1.01 0.25 2.25 3.12 2.5 8.1 6.7
2 1.2 26.37 6.0 1.5 2.15 0.25 7.47 11.16 4.0 22.7 12.5
3 1.2 56.04 14.3 3 2.06 1.5 16.28 70.82 12.2 11.6 22.4
4 1.2 28.17 6.2 3 1.73 0.5 6.93 12.81 7.7 9.8 11.3
5 1.2 68.73 5.6 6 17.45 2 83.40 157.68 4.2 24.3 17.2
6 1.2 23.51 6.7 3 1.82 0.25 4.07 15.21 9.5 6.9 8.9
3 (C2) 1.51 0.75 5.25 2.0 8.9
7 1.2 33.80 7.0 6 3.45 0.75 16.56 30.60 4.5 9.8 9.8
6 (C2) 5.26 0.5 16.05 7.8 9.5
8 1.2 31.28 5.2 3 2.43 0.25 9.84 24.05 5.1 12.6 15.7
3 (C2) 4.25 0.25 16.72 11.7 21.4
9 1.2 32.71 9.5 6 4.79 0.5 24.00 36.73 4.3 14.7 11.1
6 (Fed) 6.44 0.5 31.78 8.7 19.4
10 1.2 40.11 10.9 6 1.54 1 10.80 39.35 6.1 5.4 8.2
6 (C2) 2.85 0.75 17.84 7.2 8.9
11 1.2 34.40 10.5 6 9.04 0.25 29.32 55.59 10.4 17.0 17.0
6 (Fed) 5.74 0.75 24.80 6.0 14.4
12 1.2 24.41 8.9 6 1.63 0.25 10.39 27.76 9.7 8.5 9.5
6 (Fed) 2 1 7.14 8.2 5.8
13 1.2 30.29 6.8 6 1.75 0.5 8.12 13.89 7.8 5.4 5.1
14 1.2 27.12 4.5 6 4.40 0.5 15.07 28.78 6.2 11.1 12.0
6 (Fed) 2.09 0.75 14.26 11.1 10.5
15 1.2 40.73 18.6 6 3.45 0.5 18.82 30.71 13.0 9.2 9.4
6 (Fed) 2.45 1 9.68 11.9 4.8
16 1.2 30.03 14.6 6 6.08 0.5 22.88 40.52 6.7 15.2 15.1
17 1.2 20.75 7.2 6 2.45 0.25 10.70 40.50 4.3 10.3 14.0
6 (Fed) 3.07 1 12.37 4.1 11.9
18 1.2 15.03 1.9 6 (Fed) 0.65 0.25 3.62 14.69 3.4 4.8 6.0
6 0.77 0.5 6.78 5.0 9.0
19 1.2 19.11 4.9 6 1.77 1 7.53 3.7 7.9
6 (Fed) 3.38 0.5 9.07 3.5 9.5
Mean 31.84 8.18 3.53 0.63 15.48 36.33 6.85 11.3 11.8
s.d. 12.82 4.09 3.21 0.40 14.66 34.63 3.13 5.2 4.5
CV(%) 40 50 91 64 95 95 46 46 38
C2, second course; Cmr,, maximum concentration; AUC; area under the curve; Tmax, time to maximum concentration. Total = lactone plus acid concentrations.
Fed, after breakfast.
bioavailability from lactone is 11.3 ± 5.2% compared with an
absolute bioavailability of 11.8 ± 4.5% for total G1147211 (Table
3). The ratio of lactone to total G1147211 after intravenous
dosing was similar to the ratio after oral administration. The
median intrapatient variability of the absolute bioavailability was
31% (range 3-88%).
At the highest dose level of 6.0 mg m-2, the influence of fasted
or fed state in absorption ofthe drug was studied in eight patients.
The AUC after fasting was 15.3 ± 8.1 ng h ml and, after a break-
fast, 16.3 ± 9.7 ng h ml-' (P = 0.36, NS).
After oral administration, the terminal half-life of GI147211
lactone ranged from 2.0 to 13.0 h (mean 6.8 ± 3.1 h) and were of
the same magnitude as after intravenous administration (mean
8.1 ± 4.1 h) (P = 0.04).
Responses
Tumour responses were evaluable in 17 patients. In two patients,
tumour response could not be analysed because of early with-
drawal. Best response to treatment was stable disease in seven
patients. Short-lasting stable disease occurred in five patients with
colon cancer, in one patient with adenocarcinoma of unknown
primary and one patient with sarcoma.
DISCUSSION
The characterization of the inhibition of topoisomerase I as the
mechanism of action of CPT has resulted in the development of
several semisynthetic CPT analogues, of which some are under
extensive clinical investigation. This is the first clinical bioavail-
ability study oforally administered GI147211.
In preclinical studies, absolute bioavailability of G114721 was
2-5% in mice and 16% in dogs. In the present study, in humans the
absolute bioavailability averaged 11.3 ± 5.2%. In comparison,
bioavailability studies of topotecan showed a variable systemic
exposure of32% and 44%, which is higher than the bioavailability
of oral GI147211 (Kuhn et al, 1995; Schellens et al, 1996). The
bioavailability after oral administration ofGI14721 1 showed wide
interpatient variability ranging from 4.8% to 24.3%. Intrapatient
variability however was more limited.
There was little difference in the ratio of lactone to total
GI147211 between oral and intravenous dosing, indicating that the
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Table 4 Pharmacokinetic parameters of G1147211 lactone in 13 patients receiving 6.0 mg m-2 oral solution doses in fasted state and fed state. Eight patients
were analysed in fasted and fed states.
Patient i.v. Dose i.v. AUC i.v.t10 Oral dose OralT,.,, Oral AUC Oralt12 Absolute bioavailability
(mg m-2) (ng h ml-') (h)
Fasted Fed Fasted Fed Fasted Fed Fasted Fed Fasted (%) Fed (%)
5 1.2 68.73 5.6 6 - 2 - 83.40 - 4.2 - 24.3 -
7 1.2 33.80 7.0 6 - 0.75 - 16.56 - 4.5 - 9.8 -
9 1.2 32.71 9.5 6 Fed 0.5 0.5 24.00 31.78 4.3 8.7 14.7 19.4
10 1.2 40.11 10.9 6 - 1 - 10.80 - 6.1 - 5.4 -
11 1.2 34.40 10.5 6 Fed 0.25 0.75 29.32 24.80 10.4 6.0 17.0 14.4
12 1.2 24.41 8.9 6 Fed 0.25 0.75 10.39 24.80 9.7 6.0 8.5 14.4
13 1.2 30.29 6.8 6 - 0.5 - 8.12 - 7.8 - 5.4 -
14 1.2 27.12 4.5 6 Fed 0.5 0.75 15.07 14.26 6.2 11.1 11.1 10.5
15 1.2 40.73 18.6 6 Fed 0.5 1 18.82 9.68 13.0 11.9 9.2 4.8
16 1.2 30.03 14.6 6 - 0.5 - 22.88 - 6.7 - 15.2 -
17 1.2 20.75 7.2 6 Fed 0.25 1 10.70 12.37 4.3 4.1 10.3 11.9
18 1.2 15.03 1.9 6 Fed 0.5 0.25 6.78 3.62 5.0 3.4 9.0 4.8
19 1.2 19.11 4.9 6 Fed 1 0.5 7.53 9.07 3.7 3.5 7.9 9.5
Mean 32.09 8.53 0.65 0.69 20.34 16.30 6.61 6.84 11.4 11.2
s.d. 13.45 4.45 0.47 0.26 20.21 9.71 2.87 3.36 5.2 5.0
CV(%) 42 52 72 38 99 60 43 49 46 44
Fasted, fasted state; fed, after breakfast; AUC, area under the curve;Tm,,a, time to maximum concentration.
acid metabolite is not formated during the first pass. Tma of oral
G1147211 was 0.5 h or less in 13 of 19 cases, indicating rapid
absorption and this was not influenced by the presence of food.
Oral dosing ofGI147211 appeared to have similarblood half-lives
to the intravenous formulation, indicating no prolonged absorption
of the oral drug. In conclusion, the absolute bioavailability after
administration of an oral solution of G1147211 was low and
showed wide interpatient variability. Oral GI147211 bioavail-
ability was not dose dependent and was not affected by the pres-
ence of food. It was not possible in this study to determine the
contributions offirst-pass metabolism vs incomplete absorption to
G1147211 bioavailability.
At an oral dose of6.0 mg m-2 day-' GI147211 on day 1 followed
by injection of the drug at the dose of 1.2 mg m-2 day-' on days
2-5, the onset of neutropenia CTC grade III-IV occurred
between day 7 and 19, with a nadir count ranging from 0.09 to
0.98 x 109 1-'. The day of the platelet nadir was 8 days, ranging
from day 3 to day 16, and the value ofCTC grade III-IV thrombo-
cytopenia ranged from 4 to 40 x 109 l-l. In contrast to the findings
in our phase I study on intravenous GI147211, the current study
shows CTC grade III-IV myelotoxicity occurring in patients who
have been heavily pretreated (Gerrits et al, 1996).
In other patients, mild leucopenia (CTC grade I-TI) with slow
recovery frequently occurred, and subsequent courses had to be
postponed for 1 week in 10 out of 30 courses at the dose level of
6.0 mg m-2, irrespective of pretreatment of patients. Treatment
courses with CTC grade III-IV myelosuppression were all
uneventful except for one patient with septicaemia.
In topotecan studies, the dose-limiting toxicity was also non-
cumulative myelosuppression, predominantly a severe neutropenia
of brief duration not necessitating treatment delays (Rowinsky et
al, 1992; Verweij et al, 1993). Thrombocytopenia and anaemia
occurred mainly in regimens with prolonged intravenous topotecan
administration (Hochster et al, 1994; Creemers et al, 1996).
A single oral administration ofG1147211 did not result in diar-
rhoea. No human data are available on effects on the intestinal
mucosa with repeated oral GI147211.
Unlike GI147211, which is the active compound, CPT-l1 is a
prodrug. CPT- 11 has to be converted to the active metabolite SN-
38. Ithas been hypothesized thatbiliary excretion ofSN-38 induces
diarrhoea as a result ofa secretory and exudative mechanism. With
oral 9-nitro-camptothecin administration, 33% of patients devel-
oped CTC grade 2 II diarrhoea (Verschraegen et al, 1996).
Preclinical data have indicated that topoisomerase I inhibitors,
like topoisomerase II inhibitors, demonstrate more efficacy with
prolonged continuous exposure (Houghton et al, 1995).
An oral administration would be most convenient for prolonged
dosing. Because of the low absolute bioavailability of GI147211
and the wide range in the interpatient variation, resulting in a non-
predictable level of individual drug exposure, development of an
oral formulation seems unattractive. The intravenous route is
advised for further development of this active and promising new
topoisomerase I inhibitor.
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